TWILIGHT-Stent: Ticagrelor Monotherapy According to Stent Type

Published: 31 Aug 2021

  • Views:

    Views Icon 470
  • Likes:

    Heart Icon 1
Average (ratings)
No ratings
Your rating

Dr George Dangas (Mount Sinai Hospital, New York, NY, US) discusses the results of the TWILIGHT-Stent trial, presented at ESC 2021. This study examined the incidence of ischemic and bleeding events in patients treated with contemporary drug-eluting stents over 3-15 months. This trial also examined ticagrelor monotherapy vs ticagrelor with aspirin.

1. What were the main aims of TWILIGHT-Stent?
2. What are your key findings?
3. What are the next steps?

Filmed remotely from New York, NY, 2021.

Interviewer: Jordan Rance

Videography:Mike Knight